The inability to use powerful antituberculosis drugs in an increasing number of patients
seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified …

Background Mental health disorders, social stress, and poor health-related quality of life are
commonly reported among people with tuberculosis (TB). We conducted a systematic review …

Background With the introduction of new anti-tuberculosis drugs, all-oral regimens with
shorter treatment durations for multidrug-resistant tuberculosis have been anticipated. We …

Tuberculosis (TB) is still a major health problem worldwide. Especially, multidrug-resistant
TB (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin …

Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB)
treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB …

A phase III trial of delamanid showed acceptable safety and tolerability; however, it failed to
demonstrate superior efficacy of delamanid in terms of reduction in time to sputum …

Abstract Background Each year 25 000–32 000 children develop rifampicin-or multidrug-
resistant tuberculosis (RR/MDR-TB), and many more require preventive treatment …

Background The treatment outcomes of patients with multidrug/rifampin-resistant (MDR/RR)
tuberculosis (TB) are important indicators that reflect the current status of TB management …

Tuberculosis (TB) has afflicted people for millennia and, unfortunately, despite effective
treatment was the leading cause of death from an infection in 2016, killing 1.7 million people …

Fluoroquinolones are group A drugs in tuberculosis guidelines. We aim to compare the
culture conversion between new-generation (levofloxacin and moxifloxacin) and old …